Tamsulosin Hydrochloride Capsule
Product Images NDC 71335-1784

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 71335-1784). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351784)

This is a description of a medication called Tamsulosin HCI, which comes in a green capsule with the imprint "D;53". Each capsule contains 0.4mg of the medication and is manufactured by Aurobindo Pharma Limited. The medication is commonly used as treatment for prostate gland enlargement. The packaging displays important information about proper storage and keeping this medication out of reach of children. The product is sold in a bottle of 30 capsules and is identified by the NDC number 7133517841 and 04346301523487.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

The text is a figure description and does not provide enough information to generate a useful description.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Figure 2B represents a graph showing the mean change from baseline in the Total AUA Symptom Score (ranging from 0 to 35) in Study 2. It illustrates the mean change in the scores of patients who received treatment with different doses of a drug (0.08mg and 0.4mg) and placebo over a period of 13 weeks, as well as the LOCF (Last Observation Carried Forward).*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

This appears to be a section of a scientific study indicating the increase in peak urine flow rate as a result of a particular treatment compared to a placebo. The treatment listed is 25 -O—O-—0-08mg -A-=A=2x 0.4mg. The study involved multiple groups (n=635, n=621, n=617, n=754, n=755, n=752, n=713, n=694) and different durations of treatment (measured in weeks). The figures suggest that the treatment resulted in a significant increase in peak urine flow rate compared to the placebo.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

The figure shows the mean increase in peak urine flow rate (mL/Sec) for Study 2. The duration of treatment in weeks is plotted on the x-axis, while the treatment type is represented by different markers on the graph. However, without additional information, it is not possible to provide a more detailed or complete description of the study or its results.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.